These changes resulted in reduced IL-1β and IL-18 release and inhibition of TXNIP/NLRP3 complex formation, thereby mitigating the ALI/ARDS pathology (Qu et al., 2022; Weng et al., 2023). The gene discussed is TXNIP; the disease is acute respiratory distress syndrome.